You nailed it, buddy! We're all the same person. Anybody who disagrees with you has to be the same person.CG can never do anything wrong, and it's foolish to consider risk/reward. Good logic!!
P.S. I have longterm shares in my Roth account, but I'm pretty much done actively trading this stock. I believe in the science and that it will prevail eventually. I have doubts about management, the FDA, and how the market feels about SRPT. As anyone paying attention should.
P.P.S. Have fun with your date Rosy Palmer tonight!
Fair assumption. At some point--probably before etep is finally up for review--at least one of these boys could become non-ambulatory. I'm sure the market will love that and completely ignore the natural history of DMD, given the hatred for this stock and its CEO. The most important thing at this point is to keep to the timeline. If CG can't do it, we see single digits.
No. Hedge funds look out for themselves. Sometimes, however, what is best for a hedge fund is also best for retailers. That is the case here, so what starboard is doing is great.
Nice find by Gdubya1 on twitter. Nice to have Craig McDonald on our side.
Riiiiiight. Moving from one turrrd to the next. You want people to lose more money than they already have, huh?
The CEO did similar sells before amazing data was released. Clearly not a good barometer. The other thing folks need to remember is that these guys probably have plenty of future option grants waiting in the wings. So it's not as if they're out of shares permanently.
Um, the man in Dallas died because he received the drug more than 10 days after developing symptoms; not because the drug didn't work. Secondly, brincidofovir has had very good efficacy as an anti-viral in many other diseases, so suggesting it doesn't work is ignorant, or flat out lying.
USE YOUR HEAD AND INTELLIGENCE.
She was almost certainly treated by CMRX's drug. The news stated she was treated by an antiviral, which is what brincidofovir is.
One thing to note is that speed of treatment is a very significant factor in the drug's efficacy. We don't know how long the patient had been displaying symptoms before receiving the drug.
You're completely ignoring all risk. The market isn't. That's why we're trading at $100 right now instead of $400. As more and more positive efficacy and safety data comes out, your $400 pps will come to fruition. That's assuming all forthcoming data is positive. I think it will be, but there are risks which you seem too eager to ignore.
You're jumping the gun. It's too early for BLUE to be trading at $400, regardless of how incredible the b-thal results have been. It's still only in Phase 1/2 with only a handful of treatments. I'm of the opinion that there's a good chance BLUE will be trading $400 at or before 2016, but to suggest it should right now is hogwash.
Shorts are really dumb.
Even though you're a huge, smelly turrd, your statement is probably accurate.
I see no press release and nothing in the company's calendar of events. The company pr'ed the previous two appearances in 2013 and 2014, so I'm assuming they aren't presenting this year. Anybody know for certain?
Absolutely wrong. How many retailers predicted the bottom of the crash in 2009 correctly? Very few. Buying on margin would have wrecked most traders.
Wait, so you think people care enough to take a screenshot of your ridiculous post? BLUE isn't going to the $60s unless the entire market takes a massive dump. We'll see $200 before we see $60.